Serum/plasma 25-hydroxyvitamin D and risk of lung, breast and prostate cancer: a meta-analysis

Vitamin D has been suggested to have important effects suppress cancer development. There were several newly published studies about the association between serum 25-hydroxyvitamin D(25(OH)D) and lung, breast, or prostate cancer risk, but no conclusive or update results were available. To identify the role of serum 25(OH)D levels and cancer risk, we make a meta-analysis to evaluate the association of serum 25(OH)D levels with the three malignancy. Forty-eight studies (24 studies focused on prostate cancer, 16 on breast cancer and 8 on lung cancer) were included. The summary relative ratio (RR) with 95% confidence interval (CI) was used to assess different cancer risk. Meta-analysis of different cancer total studies showed that RR for high serum/plasma 25(OH)D levels with lung cancer was 1.08 (95% CI 0.94-1.24, P= 0.278). The RR for high serum/plasma 25(OH)D levels with breast cancer was 0.92 (95% CI 0.85-1.00, P< 0.05). The RR for high serum/plasma 25(OH)D levels with prostate cancer was 1.11 (95% CI 1.03-1.20, P< 0.01). In conclusion, our date suggests an inverse association between serum 25(OH)D and breast cancer, a positive collection with prostate cancer and a irrelevant result with lung cancer.